{"id":828241,"date":"2025-03-20T16:09:16","date_gmt":"2025-03-20T20:09:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/"},"modified":"2025-03-20T16:09:16","modified_gmt":"2025-03-20T20:09:16","slug":"allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/","title":{"rendered":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence"},"content":{"rendered":"

<\/p>\n

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence<\/b><\/p>\n

Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy<\/i><\/p>\n

NATICK, Mass.–(BUSINESS WIRE<\/a>)–
\nAllurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence.\n<\/p>\n

\n52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 medication through 8 months.\n<\/p>\n

\n\u201cI believe combining the Allurion Balloon with low-dose GLP-1 therapy has several advantages,\u201d said Dr. Luigi Flagiello, bariatric surgeon at Clinica Ruesch who oversaw this case series. \u201cThese results indicate that a combination approach increases weight loss and that by using lower doses of GLP-1s, patients do not experience as many side effects\u2014including muscle wasting\u2014and have improved adherence. Patients may also be benefiting from two distinct physiological impacts: satiety induction from the balloon and reduced hunger from the GLP-1.\u201d\n<\/p>\n

\nPrevious studies in patients undergoing GLP-1 therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost1<\/sup> and have also shown that 30% of patients discontinue GLP-1 therapy within the first month and 58% discontinue before reaching a clinically meaningful health benefit2<\/sup>, due in part to side effects, dose escalation required for continued weight loss, and cost. Semaglutide dosing is typically increased to 2.4mg, over two times higher than the maximum dose of 1.0mg used in the combination approach.\n<\/p>\n

\n\u201cMuscle wasting and lack of adherence are significant challenges for GLP-1s, and this initial data suggests that a combination approach that leverages Allurion\u2019s full program\u2014which includes the balloon, our Virtual Care Suite, and our behavior change program\u2014may be a compelling solution,\u201d said Dr. Shantanu Gaur, Founder and CEO of Allurion. \u201cWe plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.\u201d\n<\/p>\n

\nAdditional data on the combination approach is being collected as part of this case series and is expected to be presented at upcoming medical meetings.\n<\/p>\n

About Allurion<\/b><\/p>\n

\nAllurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world\u2019s first and only swallowable, ProcedurelessTM<\/sup> gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.\n<\/p>\n

\nFor more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201ctarget,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions and include statements regarding the expected efficacy of a combination approach of the Allurion Program and GLP-1 use for weight loss management, the timing and results of additional and future studies and trials involving such treatment plans, market acceptance of such new combined therapies, the uniqueness of Allurion\u2019s product and service offerings and other statements about future events that reflect the current beliefs and assumptions of Allurion\u2019s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion\u2019s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this press release, including but not limited to (i) the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii) the timing of and results from its clinical studies and trials, including those involving a combination approach to weight loss treatment, (iii) the evolution of the markets in which Allurion competes and the increasing acceptance of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v) the impact of acts of war and terrorism, including the Russia-Ukraine war and Israel-Hamas war and political instability in general on Allurion\u2019s business, (vi) Allurion\u2019s expectations regarding its market opportunities, (vii) the outcome of any legal proceedings against Allurion, (viii) the risk of economic downturns and a Allurion\u2019s ability to respond to a changing regulatory landscape in the highly competitive industry in which it operates, and (ix) uncertainties related to market conditions and economic conditions in general, including tariffs, trade wars, recessions, interest rates and currency fluctuations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K filed on March 26, 2024 and Amendment No. 1 thereto filed on April 29, 2024, the Company\u2019s Quarterly Report on Form 10-Q filed during fiscal 2024 and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.\n<\/p>\n

1<\/sup> Wilding et al. NEJM. <\/i>2021, 384, 989-1002; 10.1056\/NEJMoa2032183
\n
2<\/sup>https:\/\/www.bcbs.com\/about-us\/association-news\/most-americans-stop-weight-loss-drugs-before-seeing-meaningful-benefit<\/a><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250320757662\/en\/<\/a><\/span><\/p>\n

Global Media and Investor Inquiries
\n<\/b>
investors@allurion.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Medical Devices Health Pharmaceutical Health Technology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months … <\/p>\n

Continue reading “Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828241","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAllurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months … Continue reading "Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T20:09:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence\",\"datePublished\":\"2025-03-20T20:09:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/\"},\"wordCount\":1139,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/\",\"name\":\"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-20T20:09:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/","og_locale":"en_US","og_type":"article","og_title":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk","og_description":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% Increase in Lean Body Mass After 8 Months of Combined Therapy NATICK, Mass.–(BUSINESS WIRE)– Allurion Technologies, Inc. (\u201cAllurion\u201d or the \u201cCompany\u201d) (NYSE: ALUR), a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize muscle mass and GLP-1 adherence. 52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1.0mg over the subsequent 6 months. After 8 months … Continue reading \"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T20:09:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence","datePublished":"2025-03-20T20:09:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/"},"wordCount":1139,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/","name":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-20T20:09:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250320757662r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allurion-announces-initial-results-on-the-combination-of-the-allurion-program-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828241"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}